{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T17:24:37Z","timestamp":1770485077579,"version":"3.49.0"},"reference-count":20,"publisher":"Wiley","issue":"10","license":[{"start":{"date-parts":[[2013,9,30]],"date-time":"2013-09-30T00:00:00Z","timestamp":1380499200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"Takeda Global Research & Development Center, Inc","award":["NCT00251693"],"award-info":[{"award-number":["NCT00251693"]}]},{"name":"Takeda Global Research & Development Center, Inc","award":["NCT00251719"],"award-info":[{"award-number":["NCT00251719"]}]},{"name":"Takeda Global Research & Development Center, Inc","award":["NCT00321984"],"award-info":[{"award-number":["NCT00321984"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2013,11]]},"abstract":"Summary<\/jats:title>Background<\/jats:title>Gastro\u2010oesophageal reflux disease (GERD<\/jats:styled-content>) is characterised by symptomatic heartburn and regurgitation. Treatment with proton pump inhibitors (PPI<\/jats:styled-content>) effectively decreases heartburn symptoms, but their effects on symptomatic regurgitation are less clear.<\/jats:p><\/jats:sec>Aim<\/jats:title>To determine the impact of PPI<\/jats:styled-content> therapy on heartburn and regurgitation severity in patients with either non\u2010erosive GERD<\/jats:styled-content> (NERD<\/jats:styled-content>) or erosive oesophagitis (EE<\/jats:styled-content>).<\/jats:p><\/jats:sec>Methods<\/jats:title>Endoscopically\u2010confirmed NERD<\/jats:styled-content> patients received dexlansoprazole 30 or 60\u00a0mg or placebo in a randomised, blinded, 4\u2010week study. Endoscopically\u2010confirmed EE<\/jats:styled-content> patients received dexlansoprazole 60\u00a0mg or lansoprazole 30\u00a0mg in two 8\u2010week, randomised, blinded healing studies. The Patient Assessment of Upper Gastrointestinal Symptom Severity questionnaire, which includes a heartburn\/regurgitation subscale, was administered to assess symptom severity at baseline, and at weeks 2 and 4 of the NERD<\/jats:styled-content> study and at weeks 4 and 8 during the EE<\/jats:styled-content> trials. We defined separate subscales for heartburn and regurgitation for this post\u2010hoc analysis. Among patients with both symptoms at baseline, improvements in individual heartburn and regurgitation subscales along with the original combined heartburn\/regurgitation subscale were determined.<\/jats:p><\/jats:sec>Results<\/jats:title>In the NERD<\/jats:styled-content> and EE<\/jats:styled-content> studies, 661 and 1909 patients, respectively, had both heartburn and regurgitation at baseline. NERD<\/jats:styled-content> patients receiving dexlansoprazole 30 and 60\u00a0mg experienced significantly greater improvements in symptom severity for both heartburn and regurgitation compared with placebo. EE<\/jats:styled-content> patients receiving dexlansoprazole 60\u00a0mg had significantly greater improvements in heartburn\/regurgitation and heartburn\u2010only subscales at week 4 compared with those receiving lansoprazole.<\/jats:p><\/jats:sec>Conclusions<\/jats:title>Dexlansoprazole appears to be effective in improving both heartburn and regurgitation, and this improvement is maintained for the duration of treatment.<\/jats:p><\/jats:sec>","DOI":"10.1111\/apt.12504","type":"journal-article","created":{"date-parts":[[2013,10,12]],"date-time":"2013-10-12T01:48:15Z","timestamp":1381542495000},"page":"1303-1311","source":"Crossref","is-referenced-by-count":9,"title":["Distinguishing the impact of dexlansoprazole on heartburn vs. regurgitation in patients with gastro\u2010oesophageal reflux disease"],"prefix":"10.1111","volume":"38","author":[{"given":"D. A.","family":"Peura","sequence":"first","affiliation":[{"name":"Department of Gastroenterology & Hepatology University of Virginia Health Sciences Center Charlottesville VA USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Pilmer","sequence":"additional","affiliation":[{"name":"Takeda Global Research & Development Center, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"B.","family":"Hunt","sequence":"additional","affiliation":[{"name":"Takeda Global Research & Development Center, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Mody","sequence":"additional","affiliation":[{"name":"Takeda Pharmaceuticals International, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M. C.","family":"Perez","sequence":"additional","affiliation":[{"name":"Takeda Global Research & Development Center, Inc Deerfield IL USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2013,9,30]]},"reference":[{"key":"e_1_2_7_2_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2006.00630.x"},{"key":"e_1_2_7_3_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2009.312"},{"key":"e_1_2_7_4_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-1004-0"},{"key":"e_1_2_7_5_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10620-009-0927-9"},{"key":"e_1_2_7_6_1","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2008.08.045"},{"key":"e_1_2_7_7_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.25.7.707"},{"key":"e_1_2_7_8_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2010.04406.x"},{"key":"e_1_2_7_9_1","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2011.146"},{"key":"e_1_2_7_10_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.04013.x"},{"key":"e_1_2_7_11_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2009.03933.x"},{"key":"e_1_2_7_12_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-010-9620-x"},{"key":"e_1_2_7_13_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-004-9567-x"},{"key":"e_1_2_7_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1542-3565(04)00348-9"},{"key":"e_1_2_7_15_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2012.01.022"},{"key":"e_1_2_7_16_1","doi-asserted-by":"publisher","DOI":"10.1111\/apt.12007"},{"key":"e_1_2_7_17_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2005.02531.x"},{"key":"e_1_2_7_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/01.mcg.0000225631.07039.6d"},{"key":"e_1_2_7_19_1","doi-asserted-by":"publisher","DOI":"10.1136\/gut.2007.133470"},{"key":"e_1_2_7_20_1","doi-asserted-by":"publisher","DOI":"10.1097\/MCG.0b013e318194592b"},{"key":"e_1_2_7_21_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1442-2050.2011.01310.x"}],"container-title":["Alimentary Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fapt.12504","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/apt.12504","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,5]],"date-time":"2023-10-05T14:51:52Z","timestamp":1696517512000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/apt.12504"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,9,30]]},"references-count":20,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["10.1111\/apt.12504"],"URL":"https:\/\/doi.org\/10.1111\/apt.12504","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,9,30]]}}}